Stockscreener 앱 받기
28.80
0.35%
-0.10
시간 외 거래:
29.19
0.39
+1.35%
전일 마감가:
$28.90
열려 있는:
$28.12
하루 거래량:
646.25K
Relative Volume:
0.56
시가총액:
$2.53B
수익:
$218.71M
순이익/손실:
$-113.70M
주가수익비율:
-22.10
EPS:
-1.3034
순현금흐름:
$-73.47M
1주 성능:
-0.83%
1개월 성능:
-12.03%
6개월 성능:
-2.90%
1년 성능:
+40.69%
1일 변동 폭
$27.93
$29.18
1주일 범위
$27.89
$29.39
52주 변동 폭
$16.82
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
28.80 | 2.54B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDEAYA Biosciences Files New Shelf Registration Statement - TipRanks
IDEAYA Biosciences, Inc. Files Form 8-K SEC Report for May 5, 2026 – Company Information and Common Stock Details - Minichart
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan
IDEAYA (NASDAQ: IDYA) has $156.55M ATM capacity remaining under Jefferies sales pact - Stock Titan
IDEAYA (NASDAQ: IDYA) files shelf to sell common stock, debt and warrants - Stock Titan
IDEAYA (NASDAQ: IDYA) reports Q1 loss but holds $972.9M cash - Stock Titan
IDEAYA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IDEAYA Biosciences 1Q Loss $98.5M >IDYA - Moomoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M - Moomoo
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan
IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Insider Monkey
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - BioSpace
IDEAYA to file NDA for uveal melanoma drug under FDA fast review - Investing.com Canada
Executive pay and auditor vote headline IDEAYA (NASDAQ: IDYA) 2026 meeting - Stock Titan
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation - MSN
IDEAYA Biosciences Advances Precision Oncology with AI Discovery - HarianBasis.co
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout - Insider Monkey
IDYA (IDEAYA Biosciences Inc.) posts narrower than expected Q4 2025 loss, shares rise 4.31 percent.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
IDYA (IDEAYA Biosciences Inc.) reports narrower Q4 2025 loss than projections, but stock dips slightly in today's trading.Pro Level Trade Signals - Xã Thanh Hà
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - MSN
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel - BioSpace
IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation - simplywall.st
IDEAYA to present trial data at ASCO meeting in June By Investing.com - Investing.com Australia
IDEAYA to present trial data at ASCO meeting in June - Investing.com
Trading the Move, Not the Narrative: (IDYA) Edition - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5%Here's Why - MarketBeat
Why IDEAYA Biosciences Stock Is Suddenly Sinking - TipRanks
IDEAYA gets late-breaking ASCO slot for full uveal melanoma data - Stock Titan
Is IDEAYA Biosciences (IDYA) stock risky for investors (Builds on Momentum) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
IDEAYA Biosciences Inc : JP Morgan Raises Tar - Moomoo
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5%Should You Sell? - MarketBeat
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars - Sahm
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Tudor Investment Corp ET AL Purchases New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
Wedbush Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock - MarketBeat
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):